Pharma & Biotech Insights, Interviews & Features
Today's issue
Refine search
Pharmaceutical
Chugai starts 2026 having just celebrated its first century, just as Nicolas Henriot completes his first year leading Chugai Pharma Europe. It is a moment of symmetry that the new general manager says has sharpened the region’s sense of purpose, balancing a century of scientific heritage with a need for agility in a fast-moving European market. 12 February 2026
Pharmaceutical
As global pharma companies seek resilient supply chains, competitive manufacturing bases and access to emerging markets, Egypt is increasingly appearing on investors’ radars. The Pharma Letter spoke to Dr Ahmed Badr Eldeen, plant manager at Zeta Pharma Egypt, to understand what international investors
truly look for when assessing opportunities in the Egyptian pharmaceutical
sector. 11 February 2026
Pharmaceutical
The Russian pharmaceutical market is facing stagnation these days, which is reflected by its weak results in 2025, when sales grew by only by 0.02% compared to 2024, reaching 4.4 billion packages, reports The Pharma Letter’s local correspondent. 11 February 2026
Pharmaceutical
Russia faces a significant increase in the number of cancelled tenders during drug procurements for state needs, which is mainly due to unfavorable conditions for suppliers and low prices, reports The Pharma Letter’s local correspondent. 5 February 2026
Pharmaceutical
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry. 2 February 2026
Pharmaceutical
On January 6, 2025, the US Food and Drug Administration (FDA) issued draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products.” The guidance outlines the FDA’s expectations for the use of AI in supporting regulatory assessments of safety, effectiveness, and quality. 2 February 2026
Pharmaceutical
The India-European Union (EU) Free Trade Agreement (FTA) represents a significant opportunity for India's pharmaceutical sector, opening doors to a $572.3 billion market while reinforcing India's global healthcare leadership, reports The Pharma Letter’s India correspondent. 2 February 2026
Pharmaceutical
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. Despite technological and operational advances, startup can often be a bottleneck, resulting in delaying the point at which the first participant can be enrolled. These delays can have significant consequences for trial momentum and overall timelines. 26 January 2026
Pharmaceutical
Ossama Anter Abo Arab, chief executive of MultiCare Egypt for Pharmaceutical Industries, talks with The Pharma Letter about pharmaceutical growth in Egypt. 26 January 2026
Pharmaceutical
In an industry where many companies claim to be reinventing the wheel, it is rare to find one that is truly doing something different—and winning recognition from big pharma for doing so. 26 January 2026
Pharmaceutical
The Russian government plans to provide additional funding for the establishment of a full production cycle of a number of vaccines within the country this year and to ensure their stable supplies for state needs, The Pharma Letter’s local correspondent reports. 26 January 2026
Pharmaceutical
Menkes disease is a rare, X-linked genetic disorder caused by mutations in the ATP7A gene, which impair copper transport within the body. If left untreated, this defect leads to critically low copper levels in multiple tissues, resulting in severe neurodevelopmental impairment, connective tissue abnormalities, seizures, and typically early childhood mortality. 22 January 2026
Pharmaceutical
A Feature from Patrick Branch, Partner, Tokyo Office Head, LEK Consulting. 19 January 2026
Pharmaceutical
Russia is facing a shortage of drugs which are used for the treatment of schizophrenia, psychosis, bipolar disorder, and other similar conditions, reports The Pharma Letter’s local correspondent. 19 January 2026
Pharmaceutical
India’s pharmaceutical sector enters 2026 at the threshold of a pivotal five-year phase, focused on building the ecosystem necessary to position itself as a global innovation hub, according to Home Minister Amit Shah, The Pharma Letter’s India correspondent reports. 15 January 2026
Pharmaceutical
An Expert View from Steve Bulera, CVP and CSO, Discovery and Safety Assessment, Charles River. 8 January 2026
Pharmaceutical
An Expert View from Michelle Murray, Vice President Health, Value & Access, GSK UK Commercial. 5 January 2026
Pharmaceutical
The holiday period typically thins out formal decisions, but several regulators still published material updates spanning approvals, policy consultations, and authorization summaries. 5 January 2026
Pharmaceutical
With 2025's pharma M&A spend exceeding $150 billion—going by deals reported on by The Pharma Letter—the total was higher than the sum spent in both 2024 and 2023. 30 December 2025
Pharmaceutical
The US Food and Drug Administration (FDA) spent much of 2025 in the spotlight. Through steady drug approvals, renewed emphasis on transparency, and concrete steps to modernize its operations, the FDA’s actions this year helped shape expectations for 2026. 30 December 2025
Pharmaceutical
Chugai starts 2026 having just celebrated its first century, just as Nicolas Henriot completes his first year leading Chugai Pharma Europe. It is a moment of symmetry that the new general manager says has sharpened the region’s sense of purpose, balancing a century of scientific heritage with a need for agility in a fast-moving European market. 12 February 2026
Pharmaceutical
As global pharma companies seek resilient supply chains, competitive manufacturing bases and access to emerging markets, Egypt is increasingly appearing on investors’ radars. The Pharma Letter spoke to Dr Ahmed Badr Eldeen, plant manager at Zeta Pharma Egypt, to understand what international investors
truly look for when assessing opportunities in the Egyptian pharmaceutical
sector. 11 February 2026
Pharmaceutical
The Russian pharmaceutical market is facing stagnation these days, which is reflected by its weak results in 2025, when sales grew by only by 0.02% compared to 2024, reaching 4.4 billion packages, reports The Pharma Letter’s local correspondent. 11 February 2026
Pharmaceutical
Russia faces a significant increase in the number of cancelled tenders during drug procurements for state needs, which is mainly due to unfavorable conditions for suppliers and low prices, reports The Pharma Letter’s local correspondent. 5 February 2026
Pharmaceutical
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry. 2 February 2026
Pharmaceutical
On January 6, 2025, the US Food and Drug Administration (FDA) issued draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products.” The guidance outlines the FDA’s expectations for the use of AI in supporting regulatory assessments of safety, effectiveness, and quality. 2 February 2026
Pharmaceutical
The India-European Union (EU) Free Trade Agreement (FTA) represents a significant opportunity for India's pharmaceutical sector, opening doors to a $572.3 billion market while reinforcing India's global healthcare leadership, reports The Pharma Letter’s India correspondent. 2 February 2026
Pharmaceutical
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. Despite technological and operational advances, startup can often be a bottleneck, resulting in delaying the point at which the first participant can be enrolled. These delays can have significant consequences for trial momentum and overall timelines. 26 January 2026
Pharmaceutical
Ossama Anter Abo Arab, chief executive of MultiCare Egypt for Pharmaceutical Industries, talks with The Pharma Letter about pharmaceutical growth in Egypt. 26 January 2026
Pharmaceutical
In an industry where many companies claim to be reinventing the wheel, it is rare to find one that is truly doing something different—and winning recognition from big pharma for doing so. 26 January 2026
Pharmaceutical
The Russian government plans to provide additional funding for the establishment of a full production cycle of a number of vaccines within the country this year and to ensure their stable supplies for state needs, The Pharma Letter’s local correspondent reports. 26 January 2026
Pharmaceutical
Menkes disease is a rare, X-linked genetic disorder caused by mutations in the ATP7A gene, which impair copper transport within the body. If left untreated, this defect leads to critically low copper levels in multiple tissues, resulting in severe neurodevelopmental impairment, connective tissue abnormalities, seizures, and typically early childhood mortality. 22 January 2026
Pharmaceutical
A Feature from Patrick Branch, Partner, Tokyo Office Head, LEK Consulting. 19 January 2026
Pharmaceutical
Russia is facing a shortage of drugs which are used for the treatment of schizophrenia, psychosis, bipolar disorder, and other similar conditions, reports The Pharma Letter’s local correspondent. 19 January 2026
Pharmaceutical
India’s pharmaceutical sector enters 2026 at the threshold of a pivotal five-year phase, focused on building the ecosystem necessary to position itself as a global innovation hub, according to Home Minister Amit Shah, The Pharma Letter’s India correspondent reports. 15 January 2026
Pharmaceutical
An Expert View from Steve Bulera, CVP and CSO, Discovery and Safety Assessment, Charles River. 8 January 2026
Pharmaceutical
An Expert View from Michelle Murray, Vice President Health, Value & Access, GSK UK Commercial. 5 January 2026
Pharmaceutical
The holiday period typically thins out formal decisions, but several regulators still published material updates spanning approvals, policy consultations, and authorization summaries. 5 January 2026
Pharmaceutical
With 2025's pharma M&A spend exceeding $150 billion—going by deals reported on by The Pharma Letter—the total was higher than the sum spent in both 2024 and 2023. 30 December 2025
Pharmaceutical
The US Food and Drug Administration (FDA) spent much of 2025 in the spotlight. Through steady drug approvals, renewed emphasis on transparency, and concrete steps to modernize its operations, the FDA’s actions this year helped shape expectations for 2026. 30 December 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze